Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
• Appraise available research findings on the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize clinical decision-making.
• Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application.
• Increase participation in active research protocols by counseling appropriately selected patients with MF about the biological rationale for and available efficacy and safety data with novel investigational agents and strategies.

CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bose — Advisory Committees: Blueprint Medicines, Geron Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Keros Therapeutics, Morphic Therapeutic, MorphoSys, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc. Dr Fleischman — Advisory Committees: CTI BioPharma, a Sobi Company, Incyte Corporation; Consulting Agreement: Ionis Pharmaceuticals Inc; Speakers Bureaus: CTI BioPharma, a Sobi Company, GSK, PharmaEssentia. Dr Yacoub — Consulting Agreements: AbbVie Inc, Acceleron Pharma, Apellis, CTI BioPharma, a Sobi Company, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer Inc, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC.

MODERATOR — Dr Kuykendall — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, Protagonist Therapeutics, MorphoSys; Data and Safety Monitoring Board/Committee: Geron Corporation.

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101

Meeting Room
Seaport E-H (Second Level)